Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2008 by Imperial College London
Sponsor:
Collaborator:
The Margaret Hayton HHT Fund
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230685
First received: September 29, 2005
Last updated: May 28, 2015
Last verified: August 2008
  Purpose

The Hammersmith Hospital provides a clinical service for patients with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that is unique in the United Kingdom. Measurements obtained as part of standard clinical practice that has evolved since 1985 allow us to assess whether particular groups of individuals that we see are more prone to recognised complications such as strokes, brain abscesses, pregnancy related complications or pulmonary hypertension. We hypothesise that certain clinical characteristics will predict the susceptibility of individuals to particular complications.


Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hammersmith Hospital Patients With Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Haemorrhagic Telangiectasia

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Stroke [ Time Frame: Prospective ] [ Designated as safety issue: No ]
  • Venous thromboemboli (VTE) [ Time Frame: Prospective ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: January 2000
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients referred to the hereditary haemorrhagic telangiectasia clinical service at Hammersmith Hospital, imperial College Healthcare NHS Trust

Criteria

Inclusion Criteria:

  • Patients attending Hammersmith Hospital

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230685

Contacts
Contact: Claire L Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Locations
United Kingdom
Respiratory Medicine, Hammersmith Hospital Recruiting
London, United Kingdom, W12 0NN
Contact: Claire L Shovlin       c.shovlin@imperial.ac.uk   
Principal Investigator: Claire L Shovlin         
Sponsors and Collaborators
Imperial College London
The Margaret Hayton HHT Fund
Investigators
Principal Investigator: Claire L Shovlin Imperial College London
  More Information

Publications:

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT00230685     History of Changes
Other Study ID Numbers: IC/CLS2
Study First Received: September 29, 2005
Last Updated: May 28, 2015
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
Pulmonary arteriovenous malformations

Additional relevant MeSH terms:
Arteriovenous Fistula
Arteriovenous Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Vascular Malformations
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis
Cardiovascular Diseases
Fistula
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Pathological Conditions, Anatomical
Vascular Diseases
Vascular Fistula

ClinicalTrials.gov processed this record on August 04, 2015